BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28911880)

  • 1. Pelvic exenteration for gynecologic malignancies: Postoperative complications and oncologic outcomes.
    Romeo A; Gonzalez MI; Jaunarena J; Zubieta ME; Favre G; Tejerizo JC
    Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):121-125. PubMed ID: 28911880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies.
    Angeles MA; Mallet E; Rouanet P; Cabarrou B; Méeus P; Lambaudie E; Foucher F; Narducci F; Loaec C; Gouy S; Guyon F; Marchal F; Gladieff L; Martínez-Gómez C; Migliorelli F; Martinez A; Ferron G
    Int J Gynecol Cancer; 2020 Feb; 30(2):233-240. PubMed ID: 31796531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
    Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and management of major urinary complications after pelvic exenteration for gynecological malignancies.
    Bladou F; Houvenaeghel G; Delpéro JR; Guérinel G
    J Surg Oncol; 1995 Feb; 58(2):91-6. PubMed ID: 7844989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
    Berek JS; Howe C; Lagasse LD; Hacker NF
    Gynecol Oncol; 2005 Oct; 99(1):153-9. PubMed ID: 16054678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.
    Haidopoulos D; Pergialiotis V; Aggelou K; Thomakos N; Alexakis N; Stamatakis E; Rodolakis A
    Surg Oncol; 2022 Mar; 40():101702. PubMed ID: 35065392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary diversion after pelvic exenteration for gynecologic malignancies.
    Martínez-Gómez C; Angeles MA; Martinez A; Malavaud B; Ferron G
    Int J Gynecol Cancer; 2021 Jan; 31(1):1-10. PubMed ID: 33229410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
    Jäger L; Nilsson PJ; Rådestad AF
    Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies.
    Urh A; Soliman PT; Schmeler KM; Westin S; Frumovitz M; Nick AM; Fellman B; Urbauer DL; Ramirez PT
    Gynecol Oncol; 2013 Jun; 129(3):580-5. PubMed ID: 23480870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preliminary experience with the Miami type ileocolonic urinary reservoir in the practice of oncologic gynecology].
    Sánchez-Valdivieso E; González Enciso A; Herrera Gómez A; Chávez Montes de Oca V; Muñóz González D
    Arch Esp Urol; 2001 May; 54(4):327-33. PubMed ID: 11455766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic exenteration for primary and recurrent gynaecological malignancies.
    de Wilt JH; van Leeuwen DH; Logmans A; Verhoef C; Kirkels WJ; Vermaas M; Ansink AC
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):243-8. PubMed ID: 16950559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients.
    Houvenaeghel G; Moutardier V; Karsenty G; Bladou F; Lelong B; Buttarelli M; Delpero JR
    Gynecol Oncol; 2004 Feb; 92(2):680-3. PubMed ID: 14766266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical results of pelvic exenteration in the treatment of gynecologic cancer.
    Petruzziello A; Kondo W; Hatschback SB; Guerreiro JA; Filho FP; Vendrame C; Luz M; Ribeiro R
    World J Surg Oncol; 2014 Sep; 12():279. PubMed ID: 25200866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ileal orthotopic neobladder after pelvic exenteration for cervical cancer.
    Chiva LM; Lapuente F; Núñez C; Ramírez PT
    Gynecol Oncol; 2009 Apr; 113(1):47-51. PubMed ID: 19176235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.
    Moreno-Palacios E; Diestro MD; De Santiago J; Hernández A; Zapardiel I
    Int J Gynecol Cancer; 2015 Jul; 25(6):1109-14. PubMed ID: 25853383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.
    Jalloul RJ; Nick AM; Munsell MF; Westin SN; Ramirez PT; Frumovitz M; Soliman PT
    J Gynecol Oncol; 2018 Sep; 29(5):e68. PubMed ID: 30022632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparation between the Bricker ileal conduit vs double-barrelled wet colostomy after pelvic exenteration for gynaecological malignancies.
    Lago V; Pradillo Aramendi T; Segarra-Vidal B; Padilla-Iserte P; Matute L; Gurrea M; Pontones JL; Delgado F; Domingo S
    Eur J Obstet Gynecol Reprod Biol; 2023 Mar; 282():140-145. PubMed ID: 36716537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curative pelvic exenteration: initial experience and clinical outcome.
    Ali Uraiqat A; Al Nsour D; Mestareehy KM; Allababdeh MS; Naffa MTF; Alrabee MM; Al-Hammouri F
    Pan Afr Med J; 2023; 44():170. PubMed ID: 37455871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urological leaks after pelvic exenterations comparing formation of colonic and ileal conduits.
    Teixeira SC; Ferenschild FT; Solomon MJ; Rodwell L; Harrison JD; Young JM; Vasilaras A; Eisinger D; Lee P; Byrne C
    Eur J Surg Oncol; 2012 Apr; 38(4):361-6. PubMed ID: 22265840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration.
    Bogani G; Signorelli M; Ditto A; Martinelli F; Casarin J; Mosca L; Leone Roberti Maggiore U; Chiappa V; Lorusso D; Raspagliesi F
    Int J Gynecol Cancer; 2018 Jun; 28(5):975-982. PubMed ID: 29683876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.